Yes, I think that's the DEAR study I mentioned in my post for nmCRPC. It will be interesting when we have comparison studies of the *lutamides for my mCSPC and other scenarios, but until then, it's a bit tricky trying to extrapolate beyond what's actually been studied.

After all, one of the proven benefits of Apalutamide is delaying the progression from castrate sensitivity to castrate resistance for metastatic cancer in the first place (the TITAN study), while the DEAR study is about delaying the progression to metastatis. You're right that it could possibly end up that one *lutamide is better at both.